Print Page      Close Window     

2019 Press Releases

Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015 | 2014
April 02, 2019
Athenex Announces Appointment of John Koh as a New Board Member
BUFFALO, N.Y., April 02, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the appointment of John Koh as a Director on Athenex’s Board, effective April 1, 2019.  Mr. Koh joins the Company’s expanded Board of Directors together with recently announced additions of Dr. John Vierling, Ms. Stephanie Davis and M... 
Printer Friendly Version 
March 29, 2019
Athenex Announces Appointment of Jordan S. Kanfer to Board of Directors
Jordan Kanfer to replace SongYi Zhang, J.D., who is stepping down BUFFALO, N.Y., March 29, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the appointment of Jordan S. Kanfer, Managing Director, Convertible and Equity Research at Opti Capital Management, to its Board of Directors, effective April 1, 2019.... 
Printer Friendly Version 
March 28, 2019
Athenex Announces Appointment of Dr. Daniel Von Hoff as Chairman of the Scientific Advisory Board of Axis Therapeutics Limited
BUFFALO, N.Y., March 28, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that Dr. Daniel Von Hoff will Chair the Scientific Advisory Board of Axis Therapeutics Limited (Axis Therapeutics). Axis Therapeutics is a majority-owned subsidiary of Athenex and is an immunotherapy company focused on developing T-ce... 
Printer Friendly Version 
March 21, 2019
Athenex Announces Xiangxue Life Sciences Receives IND Allowance from China’s National Medical Products Administration for Cancer Immunotherapy Drug Candidate
This company-sponsored IND allows Xiangxue Life Sciences (XLifeSc) to proceed to the next stage of clinical studies in China Encouraging positive clinical safety and efficacy signals were observed in preliminary investigator-initiated pilot studies in China Athenex is XLifeSc’s partner (ex-China) for cancer immunotherapy development and global development of this technology is being conducted through Axis Therapeutics Limited, a joint venture between Athenex and XLifeSc BUFFALO, N.Y., March... 
Printer Friendly Version 
March 21, 2019
Athenex Announces Expansion of Board of Directors
John Moore Vierling, MD, FACP, FAASLD, AGAF, and Stephanie Davis appointed to the Board of Directors; Sheldon Trainor-De Girolamo resigns from the Board BUFFALO, N.Y., March 21, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the resignation of Sheldon Trainor-De Girolamo as a Director of the company. The... 
Printer Friendly Version 
March 11, 2019
Athenex, Inc. Announces Fourth Quarter and Year Ended December 31, 2018 Financial Results and Provides Corporate Update
Oraxol Phase III clinical trial in metastatic breast cancer fully enrolled Positive Phase III topline results of KX2-391 in actinic keratosis featured in late breaker session at recent 2019 AAD Annual Meeting A number of abstracts submitted for presentation at ASCO on six of our products, highlighting data across the entire pipeline Full year 2018 revenue was $89.1 million (after accounting for termination of the KX2-391 licensing arrangement in China that would have contributed to $14.5 mi... 
Printer Friendly Version 
March 08, 2019
Athenex to Present Preclinical Data of Oraxol in the Treatment of Angiosarcoma at the American Association for Cancer Research Annual Meeting 2019
BUFFALO, N.Y., March 08, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that an abstract highlighting the preclinical data of Oraxol (HM30181A plus oral paclitaxel) in angiosarcoma has been accepted for presentation in a Poster Session at the American Association of Cancer Research (AACR) Annual Meeting 2... 
Printer Friendly Version 
March 07, 2019
Athenex Regains Rights to KX2-391 in China
BUFFALO, N.Y., March 07, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that upon Athenex’s request, Athenex and Chongqing Jingdong Junzhuo Pharmaceutical Co., Ltd. (“Chonqing Jingdong Pharmaceutical”) have mutually agreed to terminate the licensing and partnership agreement entered into on December 30, 2... 
Printer Friendly Version 
March 04, 2019
Athenex Announces Positive Topline Results from Two Phase III Studies of KX2-391 Ointment 1% Featured in Late Breaker Program at the 2019 American Academy of Dermatology Annual Meeting
Results show that 44% and 54% of patients in studies KX01-AK-003 and KX01-AK-004, respectively, achieved 100% AK lesion clearance at Day 57 Safety profile of KX2-391 ointment may be an important competitive advantage; adherence to treatment was greater than 99% Company to host Conference Call with Key Opinion Leader today at 8:30 a.m. ET BUFFALO, N.Y., March 04, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, developme... 
Printer Friendly Version 
February 25, 2019
Athenex to Host Conference Call with Key Opinion Leader Following Oral Presentation of Phase III Results of KX2-391 Ointment in the Treatment of Actinic Keratosis at the American Academy of Dermatology Annual Meeting
Seth B. Forman, MD, CEO of ForCare Medical Group and ForCare Clinical Research, to participate in a call on Monday, March 4, 2019 at 8:30am ET BUFFALO, N.Y., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will host a conference call and webcast with a Key Opinion Leader (KOL) on Monday, ... 
Printer Friendly Version 
February 14, 2019
Athenex, Inc. to Report Fourth Quarter and Fiscal Year 2018 Earnings Results on March 11, 2019
BUFFALO, N.Y., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will release fourth quarter and fiscal year ended December 31, 2018 earnings results on March 11, 2019 before the market opens. The Company will host a conference call and live audio webcast on Monday, March 11, 2019, at 8:30 a... 
Printer Friendly Version 
February 04, 2019
Athenex Announces Late-Breaking Oral Presentation of KX2-391 Ointment in Two Phase III Studies at the American Academy of Dermatology Annual Meeting
Results from Phase III pivotal studies to be featured at Late-Breaking Research Program on March 2, 2019 BUFFALO, N.Y., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that an abstract reporting the results from two Phase III studies of KX2-391 Ointment in the treatment of actinic keratosis has b... 
Printer Friendly Version 
January 09, 2019
Athenex Announces Completion of Target Enrollment in the Oraxol Phase III Study
BUFFALO, N.Y., Jan. 09, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that target enrollment of 360 patients in the Oraxol Phase III clinical trial in metastatic breast cancer has been achieved on schedule. Athenex also reaffirms that top line data from the study is expected to be available in mid-2019. ... 
Printer Friendly Version 
January 03, 2019
Chongqing Jingdong Pharmaceutical and Athenex Announce a Strategic Partnership and Licensing Agreement to Develop and Commercialize KX2-391 in China
Chongqing Jingdong Pharmaceutical strengthens its product portfolio of innovative drugs with novel small molecule KX2-391  Athenex further builds its presence in China, broadening global reach  Athenex to receive upfront and potential development milestones, along with tiered royalties based on net sales BUFFALO, N.Y., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization... 
Printer Friendly Version